Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple SclerosisBourdette, Dennis; Hartung, Daniel · JAMA Neurology · 2015

Glatiramer acetate-specific human CD8+ T cells: Increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatmentAlexander Dressel; Antje Vogelgesang; Heinrich Brinkmeier; Michael Mäder; Frank Weber · 2006

Expression and functional activity of chemokine receptors in glatiramer acetate–specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetateRune Alexander Høglund; Anne Lise Hestvik; Trygve Holmøy; Azzam A. Maghazachi · 2011

Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacyDimitros Karussis; Dvora Teitelbaum; Camille Sicsic; Talma Brenner · 2010

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatmentZecca, Chiara; Caporro, Matteo; Disanto, Giulio; Gobbi, Claudio · Patient Preference and Adherence · 2014

Immunomodulation by the copolymer glatiramer acetateRuth Arnon; Michael Sela · 2003

Glatiramer AcetateFrançois Blanchette; Oliver Neuhaus · 2008

Glatiramer acetate in multiple sclerosisMezzapesa, Domenico M; Rovaris, Marco; Filippi, Massimo · Expert Review of Neurotherapeutics · 2005

Biperiden/trihexyphenidylReactions Weekly · 1995

NitrendipineReactions Weekly · 2003

ScopolamineReactions Weekly · 2007

ScopolamineReactions Weekly · 2012

ScopolamineReactions Weekly · 2009

Centella asiaticaReactions Weekly · 2011

Daunorubicin/mitoxantroneReactions Weekly · 2007

AnthracyclinesReactions Weekly · 1991